Blisibimod
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
B cells in general and BAFF (B cell activating factor of the tumor necrosis factor [TNF] family) in particular have been primary…
Background Targeted, biologic inhibitors of B-cell Activating Factor (BAFF) have been evaluated in Phase 3 trials in over 5000…
ABSTRACT Introduction: Blisibimod is a potent and selective inhibitor of B cell activating factor (BAFF), a mediator of…
Background Targeted, biologic inhibitors of B-cell Activating Factor (BAFF) have been evaluated in 4 large Phase 3 clinical…
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) comprises several clinical entities with diverse clinical…
Background Blisibimod (A-623, AMG 623), a potent and selective inhibitor of B-cell activating factor (BAFF), was evaluated in the…
In the last 50 years, only one drug has achieved marketing approval for treatment of systemic lupus erythematosus (SLE) by global…
Background Blisibimod, a potent inhibitor of B cell activating factor (BAFF), was evaluated in a Phase 2b clinical trial in…
Background Elevations of BAFF are observed in patients with SLE. Here we report renal findings from a Phase 2b clinical trial in…
For the first time in more than 50 years, the US Food and Drug Administration has approved a drug specifically for the treatment…